Patents Issued in August 17, 2017
  • Publication number: 20170231945
    Abstract: Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with Campylobacter. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of Campylobacter in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of Campylobacter from one animal to another.
    Type: Application
    Filed: March 14, 2017
    Publication date: August 17, 2017
    Inventors: Jafar Mahdavi, Dlawer Ala'Aldeen
  • Publication number: 20170231946
    Abstract: A method is provided of treating, preventing or ameliorating type 2 diabetes and/or a clinical condition associated with type 2 diabetes, which method comprises administering an effective amount of cafestol or a derivative thereof including esters and salts thereof to a person in need thereof. Further provided are compositions comprising cafestol and at least one additional agent suitable for treating, preventing or ameliorating diabetes and/or a clinical condition associated with diabetes. A method is also provided of increasing insulin secretion and/or increasing insulin-dependent glucose uptake, said method comprising administering an effective amount of cafestol or a derivative thereof to a person in need thereof.
    Type: Application
    Filed: June 1, 2015
    Publication date: August 17, 2017
    Inventors: Søren Gregersen, Per Bendix Jeppesen, Kjeld Hermansen, Fredrik Brustad Mellbye
  • Publication number: 20170231947
    Abstract: A method for inhibiting mammalian TOR in a cell, comprising: providing a compound of formula (1): and incubating the cell with the compound. Also provided is a method for extending life span of a subject, comprising: providing the compound; and administering the compound to the subject. Yet also provided is a method for treating a mammalian TOR activation-caused disease in a subject, comprising: providing the compound; and administering the compound to the subject.
    Type: Application
    Filed: August 2, 2016
    Publication date: August 17, 2017
    Inventors: Chin-Chuan Chen, Yann-Lii Leu, Shu-Huei Wang
  • Publication number: 20170231948
    Abstract: Cannabinoid Alcoholic Drinks (CADs) and methods for producing CADs utilize cannabinoids dissolved in ethanol The resulting cannabinoid/ethanol solution is then combined with one or more consumable alcohols to create a CAD. Cannabidiol (CBD) can be selected as the cannabinoid, and the solution of CBD and ethanol is called CBD/ethanol solution and combining it with one or more consumable alcohols yields a CAD.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 17, 2017
    Inventors: Olga Skuratovich, Filipp Mirzakhanov
  • Publication number: 20170231949
    Abstract: A cell repair agent capable of repairing cells damaged by the oxidizing power of acidic electrolyzed water or the like, and, a disinfection system capable of safely and efficiently accelerating the sterilization and cure of infected skin or intraoral wounds. The cell repair agent includes at least one type of a polyphenol represented by the following general formula (1), a polymer thereof, and a pharmaceutically acceptable salt thereof. R2 and R3 are preferably hydrogen atoms, and R1 is preferably a hydrogen atom or a hydroxyl group.
    Type: Application
    Filed: August 12, 2014
    Publication date: August 17, 2017
    Inventor: Minoru KANNO
  • Publication number: 20170231950
    Abstract: A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject, such as experiencing symptoms of perimenopause. The composition includes a phytoestrogen and lycopene in an oral dosage form. The phytoestrogen may include a plant lignan including at least one of Matairesinol, 7-hydroxymatairesinol, Secoisolariciresinol, Lariciresinol and Pinoresinol. The lycopene may include a lycopene complex having at least one of phytoene, phytofluene, beta-carotene, tocopherols and phytosterols.
    Type: Application
    Filed: May 1, 2017
    Publication date: August 17, 2017
    Inventors: JOHN A. MINATELLI, W. STEPHEN HILL, RUDI E. MOERCK, JESSICA ENGLE
  • Publication number: 20170231951
    Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.
    Type: Application
    Filed: December 20, 2016
    Publication date: August 17, 2017
    Inventors: William GARNER, Margaret GARNER, George MINNO, David GOODEN
  • Publication number: 20170231952
    Abstract: Provided herein is a composition for use in treating rosacea, the composition comprising: (a) a first component comprising a substituted or unsubstituted diindolylmethane; and (b) optionally a second component comprising a substituted or unsubstituted retinoid compound.
    Type: Application
    Filed: July 22, 2015
    Publication date: August 17, 2017
    Inventor: David ALPERT
  • Publication number: 20170231953
    Abstract: Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.
    Type: Application
    Filed: May 1, 2017
    Publication date: August 17, 2017
    Inventors: Mohamed Naguib Attala, Philippe Diaz
  • Publication number: 20170231954
    Abstract: A pharmaceutical composition or dietary supplement with antioxidant activity, mood- regulating activity and insulin-sensitizing activity, with a consequent reduction of the accumulation of adipose tissue, is described, for use in the prevention and treatment of metabolic disorders associated with menopause and climacteric. The composition of the invention comprises, as active ingredients, a combination of alpha-lipoic acid, curcumin and L-tryptophan.
    Type: Application
    Filed: August 18, 2015
    Publication date: August 17, 2017
    Applicant: Kolinpharma S.p.A.
    Inventors: Domenico Bijno, Carmine Di Vincenzo, Emanuele Lusenti, Alberto Martina, Ritapaola Petrelli
  • Publication number: 20170231955
    Abstract: EHT extract including a mixture of late eluting tryptamides and early eluting tryptamides in a weight ratio of at least about 7:1 late eluting tryptamides:early eluting tryptamides, wherein the EHT extract includes at least 30% eicosanoyl-5-hydroxytryptamide, based on the total weight of the tryptamides in the EHT extract.
    Type: Application
    Filed: October 15, 2015
    Publication date: August 17, 2017
    Inventors: Jeffry STOCK, Maxwell STOCK, Michael VORONKOV, Jose FERNANDEZ, Kristen HUBER
  • Publication number: 20170231956
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: October 28, 2016
    Publication date: August 17, 2017
    Inventors: John A. Lowe, III, M. Amin Khan
  • Publication number: 20170231957
    Abstract: The invention provides nano- and/or microparticles comprising asenapine or a pharmaceutically acceptable salt thereof, wherein said asenapine or said pharmaceutically acceptable salt thereof is embedded in a polymer matrix or encapsulated by a polymer shell, wherein the polymer matrix or the polymer shell comprises a polymer selected from polylactide, polyglycolide, and polyester copolymers comprising copolymerized units of lactic acid and/or glycolic acid, as well as a process for their production. Moreover, the invention provides pharmaceutical compositions comprising these particles.
    Type: Application
    Filed: June 11, 2015
    Publication date: August 17, 2017
    Inventor: Celal ALBAYRAK
  • Publication number: 20170231958
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination.
    Type: Application
    Filed: April 24, 2017
    Publication date: August 17, 2017
    Inventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, EMMANUEL VIAL, MICKAEL GUEDJ
  • Publication number: 20170231959
    Abstract: Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Inventors: Katsuyuki INOO, Akiko KATAYAMA, Daiki TAKANO
  • Publication number: 20170231960
    Abstract: A method of treating or preventing multiple sclerosis includes administering a therapeutically effective amount of a cyclohexane derivative represented by Formula (I): wherein A is a substituent represented by Formula (IIa) or (IIb): R1 and R2 are each independently a hydrogen atom, chlorine atom, C1-C3 haloalkyl, C1-C4 alkyl, C1-C4 alkoxy, or cyano; R3 is a hydrogen atom or chlorine atom; R4 is a fluorine atom, hydroxymethyl, or hydroxyl; R5 and R6 are each independently a hydrogen atom, fluorine atom, C1-C3 haloalkyl, carboxyl, methoxycarbonyl, ethoxycarbonyl, C1-C4 alkoxy, hydroxyl, or C2-C5 alkylcarbonyloxy, or optionally together form oxo; R7 and R8 are each independently a hydrogen atom or fluorine atom; Y is an oxygen atom or sulfur atom; and Z is a nitrogen atom or methine or a pharmaceutically acceptable salt thereof to a mammal.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 17, 2017
    Inventors: Kozue Takagaki, Mie Kaino, Hiroe Hirokawa
  • Publication number: 20170231961
    Abstract: The present invention refers to the use of the compounds E-6087 in a weekly dosage regime for the treatment of pain and inflammation associated to a degenerative joint disease such as osteoarthritis or a condition associated to any such disease such as lameness. The present invention is directed to the treatment of mammals, preferably of dogs.
    Type: Application
    Filed: October 13, 2015
    Publication date: August 17, 2017
    Applicant: ECUPHAR n.v.
    Inventors: Josep Homedes-Beguer, David Sabate-Elias
  • Publication number: 20170231962
    Abstract: Methods for modulating quorum sensing in certain Gram-negative bacteria having multiple QS systems including Las, Rhl, and Pqs with associated receptors (LasR, RhlR and PqsR) which are modulated by small molecule modulators, particularly non-native modulators. Certain combinations of modulators of Las, Rhl and Pqs exhibit improved inhibition of virulence in comparison to the respective individual modulators. In particular, certain combinations of modulators exhibit improved inhibition in nutritionally depleted environments. More specifically, certain combinations of modulators exhibit improved inhibition in environments depleted in phosphate and/or environments depleted in iron. Nutrient depleted environments can mimic environments associated with bacterial infection in humans and non-human animals. The methods are useful in particular for modulating QS in Pseudomonas and Buckholderia.
    Type: Application
    Filed: February 13, 2017
    Publication date: August 17, 2017
    Inventors: Helen BLACKWELL, Michael Welsh
  • Publication number: 20170231963
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • Publication number: 20170231964
    Abstract: Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 17, 2017
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY STEM
    Inventors: Marc COX, Rachid SKOUTA, Artem CHERKASOV
  • Publication number: 20170231965
    Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
    Type: Application
    Filed: February 14, 2017
    Publication date: August 17, 2017
    Applicant: ASTELLAS PHARMA INC.
    Inventors: YUUKI TAKAISHI, YUTAKA TAKAHASHI, TAKASHI NISHIZATO, DAISUKE MURAYAMA, EMIKO MURAYAMA, SOICHIRO NAKAMURA, KAZUHIRO SAKO
  • Publication number: 20170231966
    Abstract: An object is to find a substance which inhibits IL-2 production. IL-2 production can be inhibited by a compound represented by the following formula (I): wherein R1 to R4 and A are as defined in the present specification, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Applicant: AYUMI PHARMACEUTICAL CORPORATION
    Inventors: Toshihiro NAKAJIMA, Satoko ARATANI, Kusuki NISHIOKA, Hiroyuki AONO
  • Publication number: 20170231967
    Abstract: The disclosure provides pharmaceutical compositions comprising Bach1 Inhibitors and Nrf2 Activators. The disclosure also provides methods of treating diseases such as psoriasis, multiple sclerosis, and COPD comprising administering a Bach1 Inhibitor and a Nrf2 Activator to a subject in need thereof.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Inventor: Otis Clinton Attucks
  • Publication number: 20170231968
    Abstract: A method for treating pruritus by topically applying a composition comprising a hedgehog inhibitor compound is provided.
    Type: Application
    Filed: February 9, 2017
    Publication date: August 17, 2017
    Inventor: Ervin Epstein
  • Publication number: 20170231969
    Abstract: Edoxaban is factor X inhibitor useful for the treatment or the prevention of thrombosis or embolism. A pharmaceutical composition comprising Edoxaban, or a pharmaceutically acceptable salt thereof, a water soluble vinylpyrrolidone polymer selected from the group consisting of povidone and copovidone, and a cellulose ether, and not comprising a sugar alcohol, having good dissolution and bioavailability is provided. A process for its preparation, a dosage form comprising such composition, and the use of said pharmaceutical composition and dosage form as a medicament are also disclosed.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 17, 2017
    Applicant: Sandoz AG
    Inventors: Johannes Raneburger, Hossam Farouk
  • Publication number: 20170231970
    Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Patricia Hurter, William Rowe, Christopher R. Young, Adriana Costache, Patrick R. Connelly, Mariusz Krawiec, Yuchuan Gong, Yushi Feng, Martin Trudeau
  • Publication number: 20170231971
    Abstract: Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Joel Kaye, Hussein Hallak, Nora Tarcic
  • Publication number: 20170231972
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and method for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: November 2, 2016
    Publication date: August 17, 2017
    Inventor: Charles Michael Zacharchuk
  • Publication number: 20170231973
    Abstract: Provided herein are quinoline, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of an endoplasmic reticulum stress-caused disease. Also provided herein are methods of their use for reducing endoplasmic reticulum stress and modulating the activity of a sarcoplasmic/endoplasmic reticulum Ca2+ATPase.
    Type: Application
    Filed: November 27, 2016
    Publication date: August 17, 2017
    Inventor: Russell Dahl
  • Publication number: 20170231974
    Abstract: The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with a substantial storage component is provided.
    Type: Application
    Filed: December 1, 2016
    Publication date: August 17, 2017
    Applicant: Astellas Ireland Co., Ltd.
    Inventors: Karin Juliette Van Charldorp, Brigitte Johanna Fanny Bosman, Monique Maria Alida Klaver, Alberto Garcia Hernandez, Tennis Edwin Drogendijk
  • Publication number: 20170231975
    Abstract: The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
    Type: Application
    Filed: May 1, 2017
    Publication date: August 17, 2017
    Inventor: Ayyappan K. Rajasekaran
  • Publication number: 20170231976
    Abstract: 8?-Hydroxy-Dihydroergotamine (8?-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or disorders selected from amyotrophic lateral sclerosis (ALS), Parkinson's disease, stress/anxiety, nausea, emesis, aggression, pain, neuropathic pain, sleeplessness, insomnia, restless leg syndrome and depression using the compounds, compositions, dosage forms and administration techniques disclosed herein.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
  • Publication number: 20170231977
    Abstract: The present invention relates to a pharmaceutical dosage form for transmucosal delivery of an active agent to two or more mucosal surfaces. The dosage form is presented as a transmucosal delivery device. The devices of the invention may include at least two mucoadhesive surfaces. The devices may further include an intermediate layer disposed between the mucoadhesive layers. The pharmaceutical can be incorporated in any one or all of the mucoadhesive layers or the intermediate layer. Upon application, the device adheres to at least two surfaces, providing transmucosal delivery of the drug to at least two surfaces.
    Type: Application
    Filed: May 18, 2016
    Publication date: August 17, 2017
    Applicant: BioDelivery Sciences International, Inc.
    Inventors: Niraj Vasisht, Andrew Finn
  • Publication number: 20170231978
    Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Inventors: Bianca BRÖGMANN, Silke MÜHLAU, Christof SPITZLEY
  • Publication number: 20170231979
    Abstract: The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 17, 2017
    Inventors: Robert A. STEINER, Charles CHAVKIN, Donald K. CLIFTON, Susan REED, Victor NAVARRO
  • Publication number: 20170231980
    Abstract: The embodiments described herein include methods and formulations for treating vasculitis. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Inventor: Bruce Chandler May
  • Publication number: 20170231981
    Abstract: Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 17, 2017
    Applicant: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Tarek A. ZEIDAN, David MANSER, Kristopher Perkin, Philip CRESSWELL, Magali HICKEY, Brian STEINBERG
  • Publication number: 20170231982
    Abstract: Methods are provided of treating cardiac hypertrophy in a mammalian subject comprising administering to the subject an anti-hypertrophic effective amount of an ion channel TR-PV1 inhibitor.
    Type: Application
    Filed: May 1, 2017
    Publication date: August 17, 2017
    Inventor: Alexander Stokes
  • Publication number: 20170231983
    Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Hiroshi YAMASHITA, Nobuaki ITO, Shin MIYAMURA, Kunio OSHIMA, Jun MATSUBARA, Hideaki KURODA, Haruka TAKAHASHI, Satoshi SHIMIZU, Tatsuyoshi TANAKA
  • Publication number: 20170231984
    Abstract: The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: February 3, 2017
    Publication date: August 17, 2017
    Inventors: Shoujun Chen, Gary Bohnert, Jun Jiang, Zhiqiang Xia
  • Publication number: 20170231985
    Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.
    Type: Application
    Filed: June 10, 2015
    Publication date: August 17, 2017
    Inventors: Stuart D. Shanler, Andrew Ondo
  • Publication number: 20170231986
    Abstract: Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the ?- and ?-isoforms and selective for both ?- and ?-isoforms (PI3K-?,?, PI3K-?, and PI3K-?), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-? inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 17, 2017
    Applicant: Acerta Pharma B.V.
    Inventors: Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, Dave Johnson, Tjeerd Barf, Allard Kaptein
  • Publication number: 20170231987
    Abstract: The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) are able to relieve the loss of skeletal muscle strength or function associated with motor neuron diseases.
    Type: Application
    Filed: October 14, 2015
    Publication date: August 17, 2017
    Inventor: Ken LINDSTEDT
  • Publication number: 20170231988
    Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.
    Type: Application
    Filed: November 30, 2016
    Publication date: August 17, 2017
    Applicant: AstraZeneca UK Limited
    Inventors: Joseph Richard Creekmore, Sanjeev Huk-michand Kothari, Bradford J. Mueller, Yingxu Peng
  • Publication number: 20170231989
    Abstract: An oral disintegrating tablet which contains rosuvastatin or a salt thereof and is stable to light is provided. An oral disintegrating tablet stable to light, temperature and humidity can be provided by preparing a multi-layered tablet containing rosuvastatin or a pharmaceutically acceptable salt thereof as an active ingredient, a light stabilizer, and an inorganic salt or a basic oxide.
    Type: Application
    Filed: May 3, 2017
    Publication date: August 17, 2017
    Inventors: Kentaro HAYASHI, Toshitada TOYODA, Yoshitsugu MUGURUMA
  • Publication number: 20170231990
    Abstract: This invention is directed to a compound of formula (I): wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).
    Type: Application
    Filed: September 7, 2016
    Publication date: August 17, 2017
    Inventors: Christopher L. VANDEUSEN, Franz J. WEIBERTH, Harpal S. GILL, George LEE, Andrea HILLEGASS
  • Publication number: 20170231991
    Abstract: This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.
    Type: Application
    Filed: September 23, 2016
    Publication date: August 17, 2017
    Inventor: Richard G. Pestell
  • Publication number: 20170231992
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof that are useful therapeutics for acute coronary syndrome and related disorders.
    Type: Application
    Filed: June 18, 2015
    Publication date: August 17, 2017
    Inventor: Richard E. Gregg
  • Publication number: 20170231993
    Abstract: Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.
    Type: Application
    Filed: April 10, 2017
    Publication date: August 17, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Majid Mahjour, Feng Li, Decheng Ma, Sutthilug Sotthivirat
  • Publication number: 20170231994
    Abstract: Provided are PDE1 inhibitors of Formula I, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 30, 2017
    Publication date: August 17, 2017
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Hailin ZHENG, Jun ZHAO, Lawrence P. WENNOGLE